We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A report of multiple sclerosis patients treated by CinnoVex™ in Iran.
- Authors
Etemadifar, Masood; Mazdeh, Mehrdokht; Torabi, Hamid Reza; Ghaffarpour, Majid; Azimian, Mojtaba; Salami, Shiva; Shahkarami, Sayyed Mohammad Amir
- Abstract
Background: Recent studies present a high prevalence of multiple sclerosis (MS) in Iran. Treatment with interferon is now the first choice in management of MS. CinnoVexx™ (an interferon beta 1-a) is available in Iran, with achievement of the technology of producing beta interferon. The aim of the present study is to evaluate the efficacy and safety of CinnoVexx™ in a national study named CINA study. Methods: This study was conducted from 2007 to 2008 in cities of Tehran, Isfahan, Mashhad, Tabriz, and Shiraz. Patients with relapsing/remitting MS with 16-50 years of age and EDSS of <4 received CinnoVexx™ (30μg/week, IM) after diagnosis by a neurologist. EDSS, drug side effects, and frequency of relapse were evaluated for one year in four 3-month visits. Results: A total of 1050 patients entered the study. Complete data were collected from 627 (60%) patients. Mean age was 30.7±8.6 year and 514 (82%) were female. The most common onset presentations were sensory symptoms (44%). Changes of EDSS through the study showed a significant decrease in the last 3-month of evaluation (p<0.05). Drug side effects were observed in 47%, 50%, 61%, and 61.4% (p>0.05) and relapse was occurred in 13.4%, 15.7%, 16.9%, and 2.4% of the patients in the first, second, third, and forth evaluation visits (p=0.001), respectively. Conclusion: CinnoVexx™ prevents progression and improves clinical course of MS. The conventional side effects of beta interferon therapy, however, are observed with CinnoVexx™.
- Subjects
TEHRAN (Iran); ISFAHAN (Iran); MASHHAD (Iran); TABRIZ (Iran); SHIRAZ (Iran); IRAN; MULTIPLE sclerosis treatment; INTERFERONS
- Publication
Tehran University Medical Journal, 2010, Vol 68, Issue 1, p30
- ISSN
1683-1764
- Publication type
Article